TalkMed Group Limited's latest marketcap:
As of 06/26/2025, TalkMed Group Limited's market capitalization has reached $469.38 M. According to our data, TalkMed Group Limited is the 14340th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 469.38 M |
| Revenue (ttm) | 61.3 M |
| Net Income (ttm) | 34.34 M |
| Shares Out | 1.33 B |
| EPS (ttm) | 0.03 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 08/14/2024 |
| Earnings Date | 07/15/2025 |
TalkMed Group Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/26/2025 | S$469.38 M | 0.09% | 14340 |
| 12/31/2024 | S$591.47 M | 17.42% | 13926 |
| 12/28/2023 | S$503.7 M | -4.79% | 14831 |
| 12/27/2022 | S$529.02 M | 2.75% | 13775 |
| 12/28/2021 | S$514.84 M | -13.2% | 15017 |
| 12/31/2020 | S$593.12 M | -12.39% | 12186 |
| 12/31/2019 | S$676.97 M | -14.15% | 10019 |
| 12/31/2018 | S$788.57 M | -11.76% | 8394 |
| 12/29/2017 | S$893.71 M | 33.33% | 9027 |
| 12/29/2016 | S$670.29 M | 6.25% | 9743 |
Company Profile
About TalkMed Group Limited
TalkMed Group Limited is an investment holding company specializing in advanced medical services across multiple regions, including Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States.
Core Business Segments
- Oncology Services – Specializing in breast, colon, lung, liver, pancreatic, gastrointestinal, head and neck, genitourinary, gynecological, and hematological malignancies, as well as brain cancers, lymphoma, and leukemia.
- Cellular and Gene Therapy – Developing innovative processing platforms for cell and gene therapy, including genetic modification of immune cells and viral vector technologies.
Key Services
- Medical Oncology – Comprehensive cancer treatment and management.
- Palliative Care – Cancer pain management, home care planning, and end-of-life care services.
- Ancillary Health Services – Including CANSCREEN, a specialized cancer screening program.
- Healthcare Management – Specialist doctor and clinical staff services.
Research & Innovation
The company is actively involved in pioneering research, focusing on genetic modification of immune cells and novel viral vector technologies to enhance cellular therapy.
Founded in 1997 and headquartered in Singapore, TalkMed Group Limited operates as a subsidiary of Citibank Nominees Singapore Pte Ltd.
Frequently Asked Questions
-
What is TalkMed Group Limited's (SGX-5G3) current market cap?As of 06/26/2025, TalkMed Group Limited (including the parent company, if applicable) has an estimated market capitalization of $469.38 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does TalkMed Group Limited (SGX-5G3) rank globally by market cap?TalkMed Group Limited global market capitalization ranking is approximately 14340 as of 06/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.